



## **Pfizer Announces COVID-19: Continuity in Care for Patients with Metastatic Breast Cancer Grant Support Program**

Pfizer is committed to doing all we can to respond to the COVID-19 pandemic. We recognize the need for the rapid development of practices and processes that protect oncology patients and help them adhere to treatment while mitigating the strain on the healthcare system due to COVID-19. As part of our commitment, we are releasing this Request for Proposals (RFP) to provide financial support for organizations implementing initiatives designed to support metastatic breast cancer patients during this evolving crisis.

This competitive grant program from Pfizer Global Medical Grants (GMG) involves a publicly posted RFP that provides details regarding a specific area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. For this RFP, organizations are invited to submit an application addressing challenges in metastatic breast cancer treatment during the COVID-19 outbreak as outlined below.

## I. Eligibility

<b>Geographic Scope:</b>	United States and Europe (NOTE: All of Europe included in RFP re-release April 22, 2020)
<b>Applicant Eligibility Criteria</b>	<ul style="list-style-type: none"> <li>• Only organizations are eligible to receive grants, not individuals or medical practice groups.</li> <li>• The following may apply: hospitals; cancer centers; healthcare institutions (both large and small); professional associations; laboratories; and other entities with a mission related to healthcare improvement.</li> </ul>

## II. Requirements

<b>Date RFP Issued</b>	April 14, 2020
<b>Clinical Area</b>	Oncology – Metastatic Breast Cancer
<b>Specific Areas of Interest for this RFP:</b>	<p>The intent of this RFP is to provide support to nursing associations, cancer centers, hospitals or healthcare systems so that they may improve their systems-of-care for patients with metastatic breast cancer who receive oral cancer medicines during the COVID-19 pandemic.</p> <p>Funds are intended to be used to for initiatives that support patient adherence to treatment and reduce risk of patient exposure to COVID-19 such as home health services that allow licensed nurses to visit patients with metastatic breast cancer for potential blood draws and/or other monitoring the patient may require. The funds can be used for supplemental salary support, transportation costs, and other related items (not otherwise reimbursable by payors). Our goal is that the process of patient care delivery during the COVID-19 pandemic will be improved with this additional funding support.</p> <p>This RFP is aligned with a recent recommendation from the National Comprehensive Cancer Network (NCCN) Best Practices Committee to transition outpatient care to at-home care whenever possible (e.g., pump disconnection, administration of growth factors, hormone therapy). Ref. JNCCN—Journal of the National Comprehensive Cancer Network Safety During the COVID-19 Pandemic</p> <p><b>If selected for funding, organizations will be asked to certify that their patient-support initiative will only be used to benefit patients receiving evidence-based oral cancer medicines and that treatment decisions will not be made based upon the availability of this program.</b></p> <p><b>Organizations will also be required to create an objective assessment tool to validate a clinical risk and to document a medical need for each patient to be enrolled in programs supported by the grant.</b></p>

<p><b>Target Audience:</b></p>	<p>Metastatic breast cancer patients receiving oral anti-cancer therapies</p>
<p><b>Not in Scope</b></p>	<p>It is <u>not</u> in scope for this RFP to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Information on how to submit requests for support of clinical research projects can be found at <a href="http://www.Pfizer.com/isr">www.Pfizer.com/isr</a>.</p> <p>It is <u>not</u> in the scope of this RFP for funds to be used to purchase therapeutic agents (prescription or non-prescription), capital equipment, or PPE.</p> <p><b>Grant funds cannot be used for billable services or billable clinical time.</b></p>
<p><b>Expected Approximate Monetary Range of Grant Applications:</b></p>	<ul style="list-style-type: none"> <li>• The total available budget related to this RFP is \$1,000,000 USD. <b>(NOTE: RFP budget increased to \$1.3M USD on April 22, 2020)</b></li> <li>• Expected approximate range of grant awards: \$10,000 to \$250,000 USD. We will consider larger grants depending on the size and scope of the program.</li> </ul>
<p><b>Key Dates for Review and Approval Process:</b></p>	<p>To facilitate a rapid response, application reviews and approvals will be done on a rolling basis. Although the RFP application window is open for 6 weeks, organizations are encouraged to apply as soon as possible. We anticipate a high volume of applications and will continue to award grants until the budget is depleted.</p> <ul style="list-style-type: none"> <li>• Grant Application RFP start date: <b>April 14, 2020</b></li> <li>• Grant Application RFP closing date: <b>May 21, 2020</b></li> <li>• Anticipated Grant Award Notification Date: <b>Our intent is to review and make funding decisions on all applications within 7-10 days of submission.</b></li> <li>• Grants will be distributed following a fully executed agreement.</li> <li>• Anticipated Project Start: As soon as possible after the grant agreement is executed.</li> </ul>
<p><b>Questions:</b></p>	<ul style="list-style-type: none"> <li>• If you have questions regarding this RFP, please direct them in writing to Jacqueline Waldrop (Jacqueline.Waldrop@Pfizer.com), with the subject line "COVID-19: Continuity in Care for Patients with Metastatic Breast Cancer."</li> </ul>
<p><b>Mechanism by which Applicants will be Notified:</b></p>	<ul style="list-style-type: none"> <li>• All applicants will be notified via email by the dates noted above.</li> <li>• Applicants may be asked for additional clarification during the review period.</li> </ul>

## Quality & Process Improvement Grant Instructions

### RFP Submission Requirements

#### How to Submit:

- Please go to [www.cybergrants.com/pfizer/QI](http://www.cybergrants.com/pfizer/QI) and sign in. First-time users should click “Create your password”.
  - Select the following Primary Area of Interest: Oncology - General
  - Select the following Competitive Grant Program Name: **2020 Oncology L- COVID-19: Continuity in Care for Patients with Metastatic Breast Cancer**
  - Requirements for submission: Complete all required sections of the online application (see details below). An additional uploaded proposal is not required.
  - If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.
- IMPORTANT:** Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed by the committee.

The proposal will be accepted via the online application. An additional uploaded proposal is not required. When answering the questions in the application please keep the following in mind:

<b>Goals and Objectives</b>	<ul style="list-style-type: none"> <li>• Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).</li> </ul>
<b>Assessment of Need for the Project</b>	<ul style="list-style-type: none"> <li>• Please include a description of the need for supplemental funding in <i>your</i> health system or organization. Describe how the grant funds would be allocated to meet the need identified.</li> </ul>
<b>Target Audience</b>	<ul style="list-style-type: none"> <li>• Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project. Describe the overall population size as well as the size of your target population.</li> </ul>
<b>Project Design and Methods</b>	<ul style="list-style-type: none"> <li>• Describe the planned project and the way it addresses the established need.</li> </ul>

<b>Innovation</b>	<ul style="list-style-type: none"> <li>Describe how this project adapts existing processes or adds elements that will reduce patient risk or support patient adherence to treatment.</li> </ul>
<b>Evaluation and Outcomes</b>	<ul style="list-style-type: none"> <li>Describe how you will monitor and evaluate the project.</li> </ul>
<b>Anticipated Project Timeline</b>	<ul style="list-style-type: none"> <li>Provide an anticipated timeline for your project including project start/end dates</li> </ul>
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here</li> </ul>
<b>Organization Detail</b>	<ul style="list-style-type: none"> <li>Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.</li> </ul>
<b>Budget Detail</b>	<ul style="list-style-type: none"> <li>The budget amount requested must be in U.S. dollars (USD).</li> <li>While completing the budget please keep the following items in mind:             <ul style="list-style-type: none"> <li>Institutional overhead and indirect costs may be included within the total amount of the grant request. Examples include human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance as well as additional project expenses such as costs for publication, software license fees, and travel.</li> <li>Pfizer does not provide funding for capital equipment.</li> <li>Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects</li> </ul> </li> </ul>